Development of Neoantigen-Related Combination Immunotherapy for Pancreatic Cancer

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K08391
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: Shinshu University
• Principal Investigator: Yanagisawa Ryu 信州大学, 学術研究院医学系(医学部附属病院), 准教授 (80532043)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: Pancreatic cancer

Outline of Final Research Achievements

In this study, we found that cytotoxic T cells in the peripheral blood of some patients with pancreatic cancer who had a favorable clinical course of treatment may exhibit immunological responses to pancreatic cancer-derived cell lines. Additionally, sensitization to specific allergens was also detected in patients who had a favorable clinical course of treatment, which may have influenced the clinical course. Although the details of these effects on the patients’ background and clinical course are still under analysis, we assume the possibility of sensitization to specific allergens may favor the acquisition of antitumor immunity. Further studies investigating the relevance of anti-tumor immunity associated with neoantigens is required.

Free Research Field

Oncology

Academic Significance and Societal Importance of the Research Achievements

膵臓癌は現時点ではまだ満足できる治療成績の得られていない疾患である。予後不良例のみならず治療経過が良好であった症例の病態を併せて解明してくことで、膵臓癌全体の治療成績が改善される可能性があると考えられる。